CommodityCoverage
10 minutes ago
Thiogenesis Therapeutics (TTI.V TTIPF) is pioneering a next-generation cysteamine prodrug, designed to overcome the limitations of traditional treatments for mitochondrial and metabolic diseases. With demonstrated safety in Phase 1 trials, their lead candidate, TTI-0102, is positioned as a best-in-c